October Newsletter
If you are not on our mailing list, email us at [email protected]! You can click “contact us” in the upper right hand corner of this webpage to inquire about our Cas9 Demo batch, and HERE to watch the video of…
Julia Sakamoto
Vernal Biosciences Showcases Cutting-Edge Innovations at the 11th International mRNA Health Conference in Berlin
Experience the incredible insights Vernal has to offer regarding its cutting-edge capping technology and the exceptional quality of our mRNA. We will be showcasing this groundbreaking information through three posters at the International mRNA Health Conference in Berlin. You can…
Advantages of Cas9 mRNA for Gene Editing: Precision, Control & Cost Effective
CRISPR-Cas9 RNA-DNA complex. Structure of Cas9 endonuclease (yellow-orange) complexed with a guide RNA (blue), a target DNA (pink) and a non-target DNA (green). The revolutionary CRISPR-Cas gene editing technology has unlocked unprecedented possibilities in genome engineering, gene therapy, and cell…
Vernal Biosciences Announces Partnership with REPROCELL
Vernal is excited to announce its new partnership with REPROCELL, furthering our mission to democratize access to mRNA, a life-changing technology, around the world. REPROCELL is a trusted leader in iPSC reprograming technologies and GMP iPSC manufacturing based in Japan. Together with REPROCELL, we…
Vernal featured on Businesswire
Find our latest article on Businesswire here: Vermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing Click the orange “Contact Us” button in the top right hand corner to find out more!
Vermont Celebrates Vernal Success in a VT Digger Article
Every success has an origin story. Check out this new VT Digger article on how CEO Christian Cobaugh, Ph.D. founded Vernal Biosciences, and what makes Vernal uniquely situated to meet mRNA process development and manufacturing needs.
Vernal Announces Successful Multigram mRNA Scale-up at the New GMP Facility
Vernal has successfully demonstrated its ability to manufacture high quality mRNA using CGMP-compliant platform. We now offer the first integrated platform for CGMP production of MCB, pDNA, mRNA, and LNP at our GMP facility. Contact us today to reserve your GMP…
Vernal Biosciences featured in Endpoints News regarding latest funding!
After a successful extension of its Series A funding, Vernal Biosciences was featured in an Endpoints News article by Tyler Patchen. Find out how we are using these funds to widen our offerings and support the mRNA community, then click…
June Newsletter
Vernal had a great experience at BIO this week and we hope we were able to catch you in Boston. If not, take a quick read on Vernal updates and let us know how we can support your mRNA needs!
Revolutionizing Medicine: How mRNA Technology Engineers Next-Generation Antibodies
By Christian Cobaugh, CEO and Founder Monoclonal antibodies (mAbs) have emerged as one of the most successful drug products and biochemical reagents of the 21st century, owing to their broad range of activities, target specificity, and ease of manufacturing. There…
April Newsletter
We cannot believe it has been 2 years. Happy Birthday Vernal Biosciences! See how Vernal has grown since 2021 and expanded its capabilities for mRNA, LNP, and GMP!
Potent Immune Response with Vernal’s LNP-mRNAs
By Julia Sakamoto, Marketing Specialist The development of mRNA vaccines has been ongoing since the late 80s, but it wasn’t until the COVID-19 pandemic that this technology became widely recognized. Instead of using an antigen to trigger the body’s immune…